Michael Demurjian

Aspargo Laboratories, Inc. is a clinical-stage biopharmaceutical company developing patient-focused solutions and must-have medicines by combining our innovative science and technologies with FDA’s 505(b)(2) approval pathway and corresponding regulations in international jurisdictions to enhance currently marketed drugs with well-known pharmacology profiles.